German Mittelstand US procurement and RFP handbook.
SAM.gov, NAICS, FAR Part 9, capability statement and past-performance translation. The procedural backbone for Archetype 1.
Read the handbook →
Engagement engagements run under client confidentiality and named clients are not published. The patterns below describe the recurring before-state, misread, architecture intervention, and outcome across the firm's engagement archetypes. Each archetype is composite, drawn from multiple engagements, and structured to be useful before an inquiry rather than as proof after one.
Before-state. A 250-employee Bavarian special-purpose-machinery firm with three decades of European OEM contracts, IATF 16949 certification, and a recently opened US sales office in Indianapolis. European past performance includes named tier-1 references at BMW, Daimler, and Volkswagen Wolfsburg. The US sales lead is a German national on assignment. The website is translated into English. The Hannover Messe stand is presented bilingually. Twelve months in: zero US tier-1 wins, three US RFQs received and responded to, all declined with no specific feedback.
The misread. The US OEM purchasing organisation is reading a German-procurement-format document inside the US capability matrix. The European tier-1 references are present but unanchored to US category equivalents. The capability statement leads with company history and engineering depth and arrives at named US-comparable references on page seven. The PPAP submission package conforms to AIAG specifications but the supplier development engineer's risk assessment has scored the firm low on US-resident application engineering and US parts-and-service infrastructure, both of which sit in supplier-quality criteria the firm did not know were load-bearing.
Architecture intervention. Rebuild the US-facing capability statement in US-procurement format, leading with named US-comparable past performance translated from European tier-1 wins at category, scope, and scale. Build the US-resident application-engineering narrative against a planned US engineering hire and a stated US parts inventory architecture. Re-stage the supplier-development conversation through a sequenced re-introduction by a fiduciary referral channel that the supplier-quality engineer recognises. Run in parallel with the firm's PPAP and CSR work that belongs with the supplier's own quality team.
Outcome shape. The qualification conversation moves from declined-without-feedback to conditional approval pending US engineering hire. The firm closes the US engineering hire, posts the US parts inventory commitment, and is added to the qualified-supplier list at one Detroit Three OEM at six months from the architecture rebuild. The architecture is then reused for the second and third tier-1 wins.
Before-state. A Class IIb device cleared under MDR with strong European clinical evidence, ISO 13485 certified, three years of European hospital adoption, and a US Delaware C-corp incorporated in anticipation of FDA submission. The US site is translated. The 510(k) submission is in progress with FDA-specialist regulatory counsel. The Swiss principal expects FDA clearance to drive US adoption.
The misread. The MDR clinical evidence does not equal substantial-equivalence demonstration in the FDA frame; the predicate device strategy is being negotiated with FDA. The US clinical category is named in MDR-derived terminology that US KOLs at category-relevant academic medical centres do not use. The US payer dossier does not exist; the firm assumed FDA clearance would drive payer adoption. The US Medicare coding pathway has not been started. The US health-system procurement readiness has not been staged.
Architecture intervention. Rebuild the US commercial frame at the front, in parallel with the FDA submission. Name the US clinical category in US-legible terms. Build a US KOL panel of six advisors at category-relevant US academic medical centres. Draft the US value dossier to AMCP and US-commercial-payer standards. Begin US Medicare coding-pathway groundwork for CPT and HCPCS work as the regulatory pathway converges. Stage US health-system procurement readiness at three named integrated delivery networks. Defer all FDA submission, IDE, and quality-system work to FDA-specialist counsel.
Outcome shape. FDA 510(k) clearance arrives with the US KOL panel ready, the value dossier drafted, the CPT pathway under early review, and three IDN procurement conversations in flight. First US health-system contract is signed within four months of FDA clearance. The US adoption curve looks consistent with the European curve, twelve months earlier than the firm's pre-architecture plan.
Before-state. A Series-B Israeli cyber firm with strong technical credentials, ISO 27001 certified, BSI-aligned, and two US enterprise wins through founder relationships. The firm has begun FedRAMP Moderate authorization with a 3PAO and is targeting US federal civilian agencies. The US-facing presence is a translated home-market site. The US sales lead is an Israeli founder splitting time. The US federal sponsoring agency relationship has not been established.
The misread. The US federal contracting officer is reading the firm's site as a private-sector technology vendor, not a federal-procurement-ready partner. The FedRAMP authorization status and timeline are not surfaced on the site or the federal-program materials. The CMMC level posture, the DoD impact-level position where DoD-targeting, the ITAR and EAR position where dual-use, and the US-side support and ConMon architecture are absent. The firm's BSI alignment is treated as substitutive for FedRAMP and CMMC by the firm but not by the contracting officer.
Architecture intervention. Rebuild the US-facing federal-procurement position with the US sponsoring agency relationship surfaced, the FedRAMP authorization status and timeline stated, the CMMC level and assessment posture named, and the DoD impact-level position where applicable. Build the US-side support, continuous monitoring, and incident-response architecture into the materials. Cleared US personnel are surfaced where relevant. The federal-program presentation deck is rebuilt in US-procurement format. The US-facing federal-conference cadence is staged at RSAC, AFCEA, and AUSA. FedRAMP and CMMC authorization administration belongs with 3PAOs, C3PAOs, and US procurement counsel.
Outcome shape. The first US federal civilian agency procurement conversation moves from cold to qualified within four months. FedRAMP Moderate authorization arrives on the originally stated timeline. The DoD-side conversation opens through a prime-contractor sub-contract path the firm did not have visibility into pre-architecture. The architecture is then reused for the second and third federal procurement opportunities.
Before-state. A second-generation Singapore single-family office with thirty years of operating-business heritage in industrial manufacturing, MAS-regulated under the appropriate licence, and a stated intent to deploy US co-investment capital alongside US institutional partners. The US-facing presence is a holding-brand site and a discreet operating-brand site. The US co-investment thesis exists internally but has not been named externally. The principal expects US institutional partners to find the firm through fiduciary referrals.
The misread. The US institutional partner reads the holding-brand site as opaque and the operating-brand site as decorative. The Asia-Pacific past-performance is real but unanchored to US-investor-legible category language. The MAS-regulated wrapper signals compliance to the US partner but reads as structural opacity rather than as a credentialing signal. The Singapore family-office register, beziehungs-implizit and discretion-led, lands as missing-conviction in the US co-investor reading.
Architecture intervention. Surface the operating brand in US-investor-legible terms while maintaining the holding-brand discretion. Name the US co-investment thesis in US-investor terminology, with named US peer-set comparables. Translate the Asia-Pacific past performance into US-category-equivalent track record at scope and scale comparable to the contemplated US co-investment. Build the US-facing principal bio with operating-business credibility surfaced. Stage US institutional-partner introductions through fiduciary referral channels that the US partner recognises.
Outcome shape. The first US institutional co-investment conversation moves from courtesy meeting to memorandum-of-understanding within five months. The architecture is then reused for the second and third US co-investment relationships. The holding-brand discretion is preserved; the operating brand carries the US-facing weight.
Before-state. A DIFC-headquartered infrastructure operator with Gulf-region track record in airports, ports, and logistics terminals, expanding into US Sun Belt commercial and infrastructure procurement. The firm has built a Houston office, hired a US business development lead, and responded to four US infrastructure RFPs. The US site presents the firm's Gulf and Africa portfolio. The US BD lead has reported to the principal that US procurement officers ask the same three questions and the firm's materials do not answer them.
The misread. The DIFC standing and Gulf-Capital signals read in Dubai as institutional credentialing and read in the US as unfamiliar jurisdictional context that the US procurement officer has to evaluate before engaging on capability. The Gulf and Africa portfolio is real but not anchored to US-procurement-equivalent past performance. The US-facing materials lead with regional reach and arrive at US-relevant capability on page six. The US BD lead is responding inside a frame that has not been corrected at the front.
Architecture intervention. Rebuild the US-facing position with named US-procurement-equivalent past performance translated from Gulf and Africa wins at category, scope, and scale. Surface the US-resident principal architecture and the Houston office as load-bearing. Name the US Sun Belt category position in US-procurement-legible terms. Restage the four open US RFP conversations through a re-introduction architecture that resets the procurement officer's frame.
Outcome shape. Two of the four open US RFPs move from declined to short-list. The first US Sun Belt infrastructure win is signed at eight months from the architecture rebuild. The architecture is then reused for the next four US procurement opportunities, with the firm increasingly recognised by US procurement officers as a US-Sun-Belt-resident operator with Gulf and Africa heritage rather than as a foreign infrastructure firm.
Diagnosis precedes execution. In every archetype the firm arrived believing the work was an execution problem. The diagnostic surfaced an architecture problem that no amount of execution would have closed. The architecture work happened first, then the execution.
The home-market signals are real and load-bearing at home. The work is not to discard them. The work is to translate them into the destination buyer's reading frame. The Bavarian engineering depth, the Swiss clinical precision, the Israeli technical novelty, the Singapore family heritage, the DIFC institutional standing, all are real. None of them transfer at face value.
The signal correction is upstream of the channel. Paid acquisition, content cadence, conference presence, and outbound sequencing all depend on the signal architecture being right. Running them on uncorrected architecture compounds the misread rather than closing it.
Specialists carry the regulated work. FDA submissions, FedRAMP authorization, PPAP execution, MAS licensing, ITAR registration, US tax structuring, US legal entity formation, immigration, and procurement counsel all belong with qualified specialists. The firm builds the commercial readability layer around their work.
The architecture is reusable. The first US win is the hardest. The second and third reuse the architecture and arrive faster. The pattern is consistent across the archetypes above and across the corridor work the firm publishes elsewhere.
SAM.gov, NAICS, FAR Part 9, capability statement and past-performance translation. The procedural backbone for Archetype 1.
Read the handbook →The parallel commercial build that runs alongside the FDA pathway. Backbone for Archetype 2 with detail on US KOL, US payer, and US Medicare coding work.
Read the bridge →The federal-procurement architecture used in Archetype 3 with detail on FedRAMP Rev 5, CMMC 2.0, NIST SP 800-171, and US-side support.
Read the analysis →Holding-brand and operating-brand architecture used in Archetype 4 with detail on the governance line and the US-investor-facing surface.
Read the architecture →The Gulf-to-US procurement translation used in Archetype 5 with detail on US Sun Belt category positioning.
Read the corridor →The three engagement formats. Where each archetype above started: Sprint first for diagnosis and signal correction, Build for full commercial layer rebuild, Group Partnership for continuous architecture work.
See the formats →